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the network and new tests that might be offered is
needed urgently. A recent report by an expert working
group for the NHS Executive and the Human Genetics
Commission has recommended that the Department
of Health acts now to consolidate this network.1
The identification of genes involved in common
diseases and responses to drug treatment raises further
and even greater uncertainties for the future provision
of services. Recent developments in cancer genetics
provide useful insights. Several genes conferring a high
risk of breast, ovarian, or colorectal cancer were identi-
fied during the 1990s. These genes seem to account for
less than 5% of all cases but a higher proportion of
cases with a strong family history and young age at
diagnosis. Publicity surrounding these discoveries has
generated unprecedented pressure on regional genetic
centres, much of it from families in which the genes
concerned are unlikely to be involved. Although
centres are responding by establishing filtering mecha-
nisms to identify the minority of families at high
genetic risk, the concerns of those at moderate or low
risk can only be effectively dealt with in partnership
with primary care.
Further surges in demand for genetic information
and testing in relation to common polygenic disorders
are likely, although enthusiasts may be prone to
overestimate this demand and the utility of genetic
testing for complex polygenic diseases. By contrast, the
recent genetics scenario project from the Nuffield
Trust has emphasised the appreciable potential of
pharmacogenomics to tailor drug choice and dosage
in individual patients.2
In the face of these new developments there is a
clear need for action. Firstly, a system throughout the
United Kingdom must be consolidated for the
evaluation and implementation of new genetic tests for
rare genetic diseases. The planning of resources and
manpower for counselling and clinical services, which
are integral to genetic testing, must be included in this
process. The recent formation of a Genetics Commis-
sioning Advisory Group within the National Specialist
Commissioning Advisory Group is an important devel-
opment in this regard. Secondly, regional genetic
centres must form partnerships with primary care and
with public health to evaluate new developments in the
genetics of common diseases. Thirdly, new partnerships
will be required with other hospital based specialties.
Pathology laboratories, for example, increasingly have
the potential to identify somatic clues indicative of
inherited mutant genes. For instance, detection of insta-
bility affecting repetitive DNA sequences in cancer tissue
can suggest hereditary non-polyposis colorectal cancer.
The increasing accessibility of DNA technology will
force re-examination of the traditional divide between
the analysis of somatic and germline mutations.
The experience of regional genetic centres in deal-
ing with issues of confidentiality and the implications
of genetic testing for family members will be invaluable
in relation to these clinical and laboratory challenges. If
resourced they are well placed to provide education
and training on inherited disease for other specialties.
And as Donnai and Elles suggest, the developing role
of the genetic counsellor may be particularly relevant
to primary care.
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Predictive genetic testing is the use of a genetic test in
an asymptomatic person to predict future risk of
disease. These tests represent a new and growing class
of medical tests, differing in fundamental ways from
conventional medical diagnostic tests. The hope
underlying such testing is that early identification of
individuals at risk of a specific condition will lead to
reduced morbidity and mortality through targeted
screening, surveillance, and prevention. Yet the clinical
utility of predictive genetic testing for different diseases
varies considerably. We explore here the factors that
contribute to this variation and which will dictate the
utility of any of these new tests now or in the future.
Methods and definition of terms
The observations in this paper derive from our experi-
ence in clinical medicine, medical genetics, genetic
counselling, and molecular biology and from partici-
pation in educational programmes for generalists on
medical genetics. The definition of utility used here
Summary points
Predictive genetic testing has considerable
potential for accurate risk assessment and
appropriate targeting of screening and preventive
strategies
Most predictive tests carry a degree of uncertainty
about whether a condition will develop, when it
will develop, and how severe it will be
The value of a predictive test depends on the
nature of the disease for which testing is being
carried out, how effective treatment is, and the cost
and efficacy of screening and surveillance measures
Predictive testing must be tailored to individuals’
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encompasses all aspects of a test (individual and
societal) that render it more or less useful in the clinical
arena.
Difference from conventional medical
testing
Current and future use
A conventional medical diagnostic test, such as a blood
count or an imaging study, defines something about
the patient’s current condition. Although such
information may have implications for the future, its
overwhelming utility lies in the information it provides
about the patient’s current state.
A predictive genetic test, in contrast, informs us
only about a future condition that may (or may not)
develop. The identified risk is sometimes high—for
example, in a positive test for Huntington’s disease)—
but always contains a substantial component of uncer-
tainty, not only about whether a specific condition will
develop, but also about when it may appear and how
severe it will be. Predictive genetic tests often carry a
further element of uncertainty: the interventions avail-
able for individuals at risk are often untested, and rec-
ommendations may be based on presumed benefit
rather than observations of outcomes.1 2
These uncertainties contrast with the presentation
of predictive genetic testing in the popular media,
which often fosters an illusion that genetic risk is highly
predictable and determinative.3 A New York Times
article, for example, recently described a “genetic
report card” that would predict a baby’s health history
at birth.4 In fact, uncertainties inherent in most genetic
tests represent a major limitation to their clinical utility.
Individual versus family
Whereas conventional diagnostic testing rarely has
medical importance for anyone other than the person
tested (except in the case of communicable diseases)
predictive genetic testing typically has direct implica-
tions for family members. Concern for relatives may be
an important motivating factor for a patient wanting to
undergo such testing; some family members, however,
may resist participating in the testing because they pre-
fer not to have information about their genetic risk.
The utility of a predictive genetic test will therefore
depend on whose point of view is considered.
Utility of predictive genetic testing for
different diseases
An examination of predictive genetic testing in various
diseases helps to identify factors that determine utility.
Figure 1 shows the degree of utility for various diseases
(ranked according to how clinically useful testing
currently is). These diseases are discussed below, from
those for which testing is most useful through to those
for which testing is least useful or even harmful.
Multiple endocrine neoplasia type 2
The rare disorder multiple endocrine neoplasia type 2
results from mutations in the RET proto-oncogene.
People with the disorder are almost certain to develop
medullary thyroid carcinoma unless they undergo
prophylactic thyroidectomy.5 Studies comparing chil-
dren with multiple endocrine neoplasia type 2 who
underwent thyroidectomy with those who did not, offer
compelling evidence that such surgery reduces the
likelihood of dying from cancer.6 Predictive genetic
testing makes it possible to identify those who will ben-
efit from surgery.
This example illustrates that when predictive
genetic testing strongly predicts a deleterious clinical
outcome and an efficacious early intervention exists, it
is of high utility. Indeed, such testing for multiple endo-
crine neoplasia type 2 is the accepted standard of care
for individuals at risk.7
Haemochromatosis
Haemochromatosis is an uncommon (but not rare)
condition of tissue iron deposition, leading to diabetes,
cirrhosis, heart disease, arthritis, and gonadal dysfunc-
tion.8 Phlebotomy is a simple and effective preventive
treatment, and predictive genetic testing is therefore
useful to raise suspicion of this often elusive diagnosis.
Testing is less useful for haemochromatosis than for
multiple endocrine neoplasia type 2, however, because
of low predictive value.9 10
Although excess iron accumulation results from a
genetic predisposition, other factors contribute to the
development of clinically important iron overload,
including sex, diet, and exposure to liver toxins such as
alcohol. Thus the penetrance of the haemochromato-
sis genotype (the proportion of individuals with
genetic susceptibility who will develop the associated
clinical condition) is low. The resultant uncertainty lim-
































High utility Low utility Harmful
Highly effective and acceptable
presymptomatic intervention
No effective intervention
Fig 1 Utility in predictive genetic testing
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ventive action based only on the results of such testing
would subject many individuals who would never
develop clinical sequelae to unnecessary phlebotomy.
Colorectal cancer
About 5-10% of colorectal cancer results from inherit-
ance of a few highly penetrant gene mutations that
confer a high lifetime risk of the disease.11 Predictive
genetic testing can be useful when family history
suggests increased risk—for example, three or more
affected relatives, with one in whom the disease was
diagnosed before age 5012—and is compatible with a
diagnosis of hereditary non-polyposis colon cancer.
Affected individuals have about a 70% lifetime risk of
colorectal cancer.12 Periodic colonoscopic surveillance
of these individuals reduces the development of colo-
rectal cancer by 62% when compared with unscreened
controls,13 showing the utility of predictive genetic test-
ing in this circumstance.
However, hereditary non-polyposis colon cancer
involves other cancer risks as well. Affected women
have a high risk of endometrial cancer, as well as
increased risks of ovarian cancer, other gastrointestinal
cancers, and cancers of the ureteral tract.12 No
established surveillance strategies are available for
these other cancers.2 Thus predictive genetic testing
provides an established outcome benefit for only one
of the risks identified, and therefore although useful, it
provides less clear cut benefit than in a condition such
as multiple endocrine neoplasia type 2.
Breast and ovarian cancer
About 5-10% of breast and ovarian cancers result from
the inheritance of mutations in the BRCA1 or BRCA2
gene.14 Predictive genetic testing for breast and ovarian
cancer, as for hereditary non-polyposis colon cancer,
can be useful to identify those at increased risk. In both
breast and ovarian cancer, however, utility is limited
because of considerable uncertainty about the predic-
tive value of the test.
A woman carrying a mutation in the BRCA1 or
BRCA2 gene may develop breast cancer, ovarian can-
cer, both cancers, or neither. Penetrance estimates
range from 36-85% for breast cancer and 10-44% for
ovarian cancer.15–17 Moreover, the age at which cancer
occurs is widely variable. These uncertainties probably
reflect a combination of factors, including the environ-
ment, modifying genes, the nature of a woman’s
specific mutation, and purely stochastic processes.
The utility of predictive genetic testing for breast
and ovarian cancer is further limited by the nature of
available surveillance and prevention strategies. Start-
ing mammography at age 25 to 35 is recommended
for carriers of the BRCA1 or BRCA2 gene, but the
efficacy of this early surveillance is unknown.1 Because
mammography is already widely encouraged for
women aged over 40 (in the United States) or 50 (in the
United Kingdom), information on genetic susceptibil-
ity is less relevant at later ages. Finally, adequate
surveillance for ovarian cancer is not available.1
Chemoprevention with tamoxifen shows promise
for reducing risk of breast cancer,18 but conflicting data
exist.19 20 Moreover, chemoprevention increases risk of
endometrial cancer and venous thromboembolic
disease. Oral contraceptives may reduce risk of ovarian
cancer but may also increase risk of breast cancer.21
Prophylactic oophorectomy and mastectomy are
reasonable options for some women and seem to be
effective in reducing cancer risk.22 23 Such measures
carry substantial burdens, however, and mastectomy in
particular is not widely accepted by women at risk.24
In short, knowledge of an inherited predisposition
to breast or ovarian cancer does not lead to simple,
straightforward measures to reduce risk, thus limiting
the utility of predictive genetic testing.
Alzheimer’s disease
Alzheimer’s disease illustrates the potential for predic-
tive genetic testing to cause harm. Measurement of the
apolipoprotein E genotype can predict risk of develop-
ing Alzheimer’s disease in people of European
descent.25 26 Two copies of the apolipoprotein E4 gene
(present in 2% of the general population25 26) are associ-
ated with a 10-fold increased risk of Alzheimer’s
disease25; one copy is associated with a twofold increased
risk, and the inheritance of an apolipoprotein e2 allele is
protective.26 Thus a positive test is an imprecise measure
of risk and could result in anxiety, stigmatisation, or dis-
crimination. The principle of avoiding harm suggests
that currently such testing would generally be unethical
because no effective prevention is available.27 28
Factors affecting utility
The ideal context, therefore, is a highly predictive test
for a disease that is serious and incurable but prevent-
able by means that are imperfect or expensive. The
table shows factors affecting utility of predictive genetic
testing.
Severity of disease and availability of effective
treatment
The utility of predictive genetic testing declines when a
disease is curable. Testing for tuberculosis, for example,
makes little sense, even though genetics contributes to
susceptibility to the disease.29 Similarly, as scientific
advances make breast or colon cancer curable by
increasingly innocuous means, the utility of predictive
genetic testing will decline.
Screening and prevention
Effective and inexpensive screening methods also
make predictive genetic testing less useful because
these measures can be readily applied to the entire
population. Testing for hypertension makes little
sense—despite evidence of strong genetic contributors
Factors affecting utility of predictive genetic testing
Increased utility Decreased utility
High morbidity and mortality of disease Low morbidity and mortality of disease
Effective but imperfect treatment Highly effective and acceptable treatment
High predictive power of the genetic test
(high penetrance)
Poor predictive power of the genetic test
(low penetrance)
High cost or onerous nature of screening and
surveillance methods
Availability of inexpensive, acceptable, and effective
screening and surveillance methods
Preventive measures that are expensive or
associated with adverse effects
Preventive measures that are inexpensive, efficacious,
and highly acceptable—for example, vaccination
“Never make predictions . . . especially about the
future”
Samuel Goldwyn Sr, Hollywood producer
Education and debate
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to this condition30—because universal screening and
treatment are the rule. As the expense of screening
rises, predictive genetic testing becomes more appeal-
ing. Thus, if magnetic resonance imaging (which is
expensive) were shown to be superior to mammogra-
phy (less expensive) in screening for breast cancer, test-
ing could target those who would benefit most.
Available preventive measures must be either
imperfect or expensive for predictive genetic testing to
be of high utility. Testing makes sense in women at high
risk of breast or ovarian cancer if they are considering
oophorectomy or mastectomy: a positive test would
confirm risk and support the use of invasive, imperfect
interventions. When prevention is simple, however, the
value of testing decreases. Vaccination is so cheap, safe,
and effective that universal administration is rational.
Thus testing has no utility in measles, mumps, or
rubella despite evidence of genetic differences in
susceptibility to infectious disease.29 The same would
be true if an effective, safe, and inexpensive vaccination
existed for breast cancer.
Perceptions of utility
Family history and experience are important factors in
determining how an individual perceives the utility of
predictive genetic testing. Figures 2 and 3 show how a
woman’s perception of the utility of testing for risk of
breast cancer, for example, can vary depending on
whether other close relatives have died of the disease
or on her own family structure.
Conclusion
Predictive genetic testing has great potential for
accurate risk assessment and for guiding the use of an
expanding armamentarium of screening and preven-
tion methods. The utility of testing varies widely,
however, depending on the magnitude of risk, the
accuracy of risk prediction, options available to reduce
risk, an individual’s previous experience, and the needs
and experience of family members. In addition, the
utility of a given predictive genetic test is likely to
change over time as knowledge grows, new strategies
for prevention are developed, and costs change. The
complexity of these factors calls for discussions about
testing that are highly tailored to the testing context
and the individual’s needs and preferences.
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the guidance that predictive genetic testing can provide in making
such decisions. Her counterpart (arrowed) in family B may perceive
breast cancer to be a less traumatic disease and feel comfortable
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Genetic risk and behavioural change
Theresa M Marteau, Caryn Lerman
Predictive genetic testing is currently used mainly for
untreatable conditions, such as Huntington’s disease,
or prenatal detection of serious genetic disorders such
as cystic fibrosis. Prenatal tests are usually accompa-
nied by an offer of termination of affected pregnancies.
Genes have now been isolated that are associated with
potentially preventable diseases such as heart disease
and cancer and with increased risk from smoking and
obesity. This has raised the possibility of providing
predictive information to many more people. Such
information may eventually reduce disease by facilitat-
ing the development of better targeted and more effec-
tive treatment.
Informing people of their genetic susceptibility to
disease may motivate them to change their behaviour
to reduce their risks. However, changing behaviour is
often difficult. In this article we review the limited
evidence concerning behavioural responses to genetic
information on risk. We use this and the literature on
behavioural change to consider if and how behaviour
might be changed in response to genetic information.
Methods
We searched Medline, PsycINFO, and the Social Science
Citation Index using the following terms: health be-
havior; illness behavior; genetic screening or mass
screening; cancer screening, health screening, mam-
mography, or preventive medicine; genetic counselling,
genetic disorders, genetic linkage, or genetics; and at risk
populations. In addition, we searched citations of key
papers, recent reviews of the subject, and conference
proceedings (using the Web of Science).
Changing health related behaviour
Just telling people that they are at risk of developing a
disease is rarely sufficient to change behaviour.1 The
interventions that are most likely to work are those that
Summary points
Changing behaviour is difficult
Behavioural change is most likely in motivated
people who participate in effective interventions
Providing people with genetic information on risk
may not increase their motivation to change
behaviour and in some cases may decrease
motivation
Behavioural change may be more likely if people
are persuaded that changing their behaviour can
reduce the risk of an adverse health outcome and
they are given access to evidence based
interventions
Further research is needed to evaluate
programmes in which genetic risk information is
given, including evaluation of different ways of
giving information
Effective interventions to change behaviour after
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